{"schema_version":"secwatch.filing_event.v1","accession":"0001013762-25-002271","form_type":"8-K","ticker":"HOTH","cik":"0001711786","company_name":"Hoth Therapeutics, Inc.","filed_at":"2025-03-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.545635+00:00","generated_at":"2026-05-24T05:51:24.811618+00:00","sec_items":["1.01","4.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Hoth restates 2023, 2024 financials for prepaid R&D errors; initiates HT-KIT toxicity study","bullets":["Restatement: prepaid expenses understated by $722,765 at Dec 31, 2023; R&D expenses understated by $260,732 for FY2023.","Quarterly restatements for 2023-2024: prepaid assets understated by $442k-$983k; R&D expenses understated by $52k-$280k.","Enters Project Order with OnTargetx for 4-week IV toxicity study of HT-KIT (mast cell cancer) at cost of $354,219.","Restatement impacts operating cash flows but total cash unchanged; 2024 10-K to include restated periods."],"urls":{"canonical":"https://secwatch.observer/filing/0001013762-25-002271","json":"https://secwatch.observer/filing/0001013762-25-002271.json","markdown":"https://secwatch.observer/filing/0001013762-25-002271.md","text":"https://secwatch.observer/filing/0001013762-25-002271.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711786/000101376225002271/0001013762-25-002271-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711786/000101376225002271/ea0235633-8k_hoth.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T05:51:24.811618+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}